Dipiperon (Pipamperon): Effects and Application

Dipiperon is the best-known brand name for Pipamperon, a low-potency antipsychotic from the butyrophenone class. In Germany, Pipamperon is approved for treating psychomotor agitation, severe sleep disorders, and behavioral disturbances in psychiatric conditions. In clinical practice, Dipiperon is frequently used in geriatric and psychiatric settings, especially for sleep disturbances with restlessness or behavioral problems associated with dementia.

Compared to high-potency antipsychotics such as haloperidol, Pipamperon has weaker antipsychotic effects but a more pronounced sedating effect and lower risk of extrapyramidal motor side effects. It exemplifies how a substance with classical antipsychotic classification is used primarily for sedation and sleep regulation in practice. Critical evaluation of indication is particularly important in older adults, because the entire drug class risks (cerebrovascular events, increased mortality in dementia) apply here as well.

Mechanism of Action

Pipamperon is an antagonist at multiple receptors with varying affinity. The primary action is blockade of serotonin 5-HT2A receptors, followed by moderate blockade of dopamine D2 and D4 receptors. Additionally, Pipamperon blocks alpha 1 adrenergic receptors, contributing to hypotension and sedation, as well as histaminergic H1 receptors, explaining the pronounced sleep-inducing effect.

Due to relatively weak D2 blockade, antipsychotic potency is less pronounced than with high-potency antipsychotics. Extrapyramidal motor side effects (dystonias, akathisia, parkinsonism, tardive dyskinesias) are rarer. The half-life is approximately 17 hours, with metabolism occurring mainly hepatically via multiple CYP enzymes including CYP3A4 and CYP2D6.

In sleep disorders, effects often occur within the first hour. Clinically visible effects on agitation and behavioral disturbances may develop over several days. Pipamperon is metabolized to inactive metabolites and primarily excreted renally.

Indications

• Psychomotor agitation, particularly in the context of underlying psychiatric disorders
• Sleep disturbances with restlessness, frequently in geriatric psychiatric practice
• Behavioral disturbances in dementia such as nocturnal restlessness, aggression, wandering, for short-term symptom control
• Adjunctive therapy in schizophrenic psychosis, primarily for sedation and improved nighttime rest
• Off-label use in chronic sleep disorders in specialized settings when standard therapies have failed

Dipiperon is not first-line treatment for acute schizophrenia without pronounced agitation symptoms, because antipsychotic efficacy is limited. For pure sleep disturbances without psychiatric comorbidity, it should be used very cautiously, as alternatives with better safety profiles exist.

Dosage and Administration

Sleep disturbances with restlessness in adults: 20 to 40 mg one to two hours before bedtime. Maximum 80 mg per evening based on individual tolerability.

Agitation states: 40 mg three times daily, individual adjustment possible. Maximum daily dose 360 mg.

Dementia-related behavioral disturbances: Start with 10 to 20 mg at night, cautious dose escalation. Due to risks in dementia patients, restrictive indication and use as briefly as possible.

Administration: Oral solution and tablets are bioequivalent. Solution is helpful in patients with swallowing difficulties and in geriatric care. Take with or without food, preferably in the evening when sedating effect is desired.

Renal impairment: Consider dose adjustment with moderate impairment, caution with severe insufficiency. Hepatic impairment: Use lower doses with liver dysfunction. Elderly patients: Halve starting dose, slow titration, short-term use if possible.

Adverse Effects

Very common: Drowsiness, daytime somnolence, dry mouth.

Common: Dizziness, orthostatic hypotension with fall risk, headache, constipation, appetite changes, weight gain with long-term use.

Occasional: Extrapyramidal motor symptoms (tremor, akathisia, parkinsonism, acute dystonia), confusion, sleep changes, hyperprolactinemia with galactorrhea and menstrual disturbances.

Rare but relevant: Tardive dyskinesias with long-term therapy, neuroleptic malignant syndrome with fever, muscle rigidity, altered consciousness and elevated CK. Immediate discontinuation and intensive care management required.

Cardiac: QT prolongation, especially in combination with other QT-prolonging substances or electrolyte disturbances, ECG prior to therapy initiation in at-risk patients.

Use in dementia: Increased mortality and stroke risk in elderly dementia patients, applies to the entire drug class.

Drug Interactions

• Other centrally acting depressants (benzodiazepines, Z-drugs, opioids, alcohol, first-generation antihistamines): enhanced sedation, fall risk, possible respiratory depression.
• Other QT-prolonging drugs (methadone, haloperidol, certain antibiotics and antifungals, citalopram at higher doses, trazodone): cumulative QT prolongation with risk of Torsade de Pointes.
• CYP3A4 inhibitors (itraconazole, ketoconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice) and CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion): elevated Pipamperon levels, increased adverse effects.
• Antihypertensive agents: additive hypotension, especially with alpha blockers.
• L-Dopa and dopamine agonists: mutual reduction of effects.
• Serotonergic agents: theoretically increased risk of serotonin syndrome, low clinical relevance.
• Lithium: rarely neurotoxic symptoms when combined with antipsychotics, EEG and clinical monitoring.

Special Precautions

Pregnancy: Data limited. Therapy should only occur if maternal benefit outweighs potential fetal risk. Third trimester: reports of neonatal adjustment disorders with sedation, irritability or respiratory problems. Lactation: Transfer to breast milk occurs, breastfeeding during therapy is generally not recommended.

Children and adolescents: Limited data, use only under specialized child psychiatric supervision.

Elderly patients: Increased sensitivity, fall and syncope risk, cognitive decline with prolonged use. Indication should be regularly reviewed and therapy kept as brief as possible. Geriatric screening tools like Priscus classify Pipamperon as problematic.

Before starting therapy: ECG in patients with cardiac risk factors, electrolytes (potassium, magnesium), liver values, kidney values. In dementia patients, inform about increased cerebrovascular and mortality risk.

Driving ability: Often impaired, especially initially and the following day, individual assessment required.

Lifestyle: Sleep hygiene, social activation, light-based daily structure and non-pharmacological measures should be optimized before and during therapy, especially for dementia-related sleep disorders.

You Might Also Be Interested In

• Levomepromazin, sedating low-potency antipsychotic
• Perazin, medium-potency antipsychotic
• Prothipendyl, sedating antipsychotic for sleep disturbances with restlessness
• Aripiprazol, partial dopamine agonist with different profile
• Donepezil, cholinesterase inhibitor in dementia therapy

Frequently Asked Questions

Sources

• Gelbe Liste, Pipamperon active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, S3 Guidelines for Sleep Disorders, Dementia and Schizophrenia
• Priscus 2.0 List, potentially inappropriate medication in older age